Source: Annual Congress 2009 - Asthma treatment and control strategies in primary care
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Zhang, F. De Vries, E. Setakis, T. P. van Staa (London, United Kingdom; Utrecht, Netherlands). Patterns of risk of death and asthma-related adverse outcomes in adult asthma patients receiving long-acting β₂-agonist (LABA) therapy: results from the UK general practice research database (GPRD). Eur Respir J 2009; 34: Suppl. 53, 1375

Member's Comments

No comment yet.

Related content which might interest you: Long-acting beta2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD Source: Eur Respir J 2010; 36: 494-502 Year: 2010 Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events: A population-based study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 COVID-19 risk and outcomes in adult asthmatics treated with biologics or systemic corticosteroids: nationwide real-world evidence. Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Inhaled corticosteroid withdrawal may improve outcomes in elderly patients with COPD exacerbation: a nationwide database study Source: ERJ Open Res, 6 (1) 00246-2019; 10.1183/23120541.00246-2019 Year: 2020 Dispensed asthma therapy and medical resource utilisation in asthma patients: results from the L777 observational study Source: Annual Congress 2009 - Epidemiology of asthma Year: 2009 Long-acting anti-muscarinic agents (LAMA) frequency of use and clinical features of patients with severe asthma in real-life setting: data from the Severe Asthma Network in Italy (SANI) registry Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 SABINA: global programme to evaluate prescriptions and clinical outcomes related to short-acting ß2-agonist use in asthma Source: Eur Respir J, 55 (2) 1901858; 10.1183/13993003.01858-2019 Year: 2020 Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Changes in prescriped inhaled COPD medication during a 3 year period in Denmark. A registry study Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013 SABA and ICS use among mild asthma patients in UK primary care Source: International Congress 2019 – Asthma treatment: cohorts and real-world studies Year: 2019 Pattern of risk of myocardial infarction (MI) in patients taking asthma medication: a study with the UK general practice research database (GPRD) Source: Annual Congress 2009 - Comorbidities and case management in primary respiratory care Year: 2009 Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013 Improvement in asthma control and reduction in medical resource use following treatment with montelukast (PRAACTICAL Study) Source: Eur Respir J 2005; 26: Suppl. 49, 576s Year: 2005 Are SABA-reliant asthma patients receiving adequate ICS therapy? A nationwide cohort study in Sweden (HERA) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Overuse of short-acting ß2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme Source: Eur Respir J, 55 (4) 1901872; 10.1183/13993003.01872-2019 Year: 2020 Risk of asthma-related emergency department (ED)/hospitalization events in patients with consistent, variable or intermittent inhaled corticosteroids (ICS) Source: Eur Respir J 2005; 26: Suppl. 49, 220s Year: 2005 QVA149 does not increase the risk of cardio- and cerebro-vascular events, pneumonia and exacerbation events compared with placebo: A network meta-analysis across multiple safety databases Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 An electronic alert to reduce excessive prescribing of short-acting beta2-agonists for people with asthma in East London: a retrospective case-control study using routine primary care data Source: Virtual Congress 2020 – Digital health interventions in respiratory medicine Year: 2020